| Assay ID | Title | Year | Journal | Article |
|---|
| AID183049 | Compound was tested for the percentage inhibition at 0.3 mg/kg in carrageenan air pouch assay. | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID1906083 | Analgesic activity in acetic acid induced ICR mouse assessed as average writhing times at 6.25 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins (Rvb = 26.1 +/- 16.3 No_unit) | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID270014 | Inhibition of COX2 | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID27648 | In vivo mean elimination half life in the female dogs by intravenous administration of the compound | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID269465 | Inhibition of human recombinant COX2 expressed in sf9 cells infected with baculovirus at 10 uM | 2006 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
| N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors. |
| AID1906092 | Antinociceptive activity in acetic acid induced ICR mouse assessed as inhibition effect at 6.25 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID270017 | Anti-inflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 3 mg/kg, iv after 5 hrs | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID251823 | Percentage inhibition of rat carrageenan-induced paw edema after iv administration at 3 mg/kg | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
| New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. |
| AID27647 | In vivo mean elimination half life in the cynomolgus monkeys by intravenous administration of the compound | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID270016 | Anti-inflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 3 mg/kg, iv after 3 hrs | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID1906171 | Aqueous solubility of the compound at pH 7.8 | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID1906087 | Analgesic activity in acetic acid induced ICR mouse assessed as average writhing times at 3.13 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins (Rvb = 26.1 +/- 16.3 No_unit) | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID270013 | Inhibition of COX1 | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID104513 | Evaluated in vivo for oral dose required to produce antiinflammatory activity in the rat paw edema assay (male Wistar rat) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation. |
| AID270020 | Gastric toxicity in rat at 40 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID1906076 | Analgesic activity in iv dosed ICR mouse assessed as reduction in acetic acid induced writhing administered for 15 mins followed by acetic acid injection and measured within 15 mins | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID178719 | Compound was tested for the chronic antiinflammatory activity in rat adjuvant arthritis model | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID270015 | Selectivity index, IC50 for COX1 over IC50 for COX2 | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. |
| AID269463 | Inhibition of microsomal COX1 at 10 uM | 2006 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
| N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors. |
| AID269471 | Anti-inflammatory activity in orally dosed Wistar rat assessed as reduction of carrageenan-induced paw edema at 0.3 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
| N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors. |
| AID1906086 | Analgesic activity in acetic acid induced ICR mouse assessed as average writhing times at 50 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins (Rvb = 26.1 +/- 16.3 No_unit) | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID1906093 | Antinociceptive activity in acetic acid induced ICR mouse assessed as inhibition effect at 12.50 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID27649 | In vivo mean elimination half life in the male rat by intravenous administration of the compound | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID1906084 | Analgesic activity in acetic acid induced ICR mouse assessed as average writhing times at 12.50 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins (Rvb = 26.1 +/- 16.3 No_unit) | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID104516 | In vivo oral dose required to produce antiinflammatory activity in the rat paw edema assay (male Wistar rat); Not determined | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation. |
| AID1906078 | Antiinflammatory activity in carrageenan-induced Sprague-Dawley rat assessed as paw withdrawal threshold measured after 2.5 hrs by paw pressure test | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID178344 | Compound was tested for complete blockade of carrageenan induced hyperalgesia within 1 hr after iv administration | 2000 | Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
| N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. |
| AID1906085 | Analgesic activity in acetic acid induced ICR mouse assessed as average writhing times at 25 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins (Rvb = 26.1 +/- 16.3 No_unit) | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID1906095 | Antinociceptive activity in acetic acid induced ICR mouse assessed as inhibition effect at 50 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID1906094 | Antinociceptive activity in acetic acid induced ICR mouse assessed as inhibition effect at 25 mg/kg, iv administered for 15 mins followed by acetic acid injection and measured within 15 mins | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |